iBio
- Revenue$2.4 MFY, 2021
- Market Capitalization$51.3 M2022-07-26
OverviewSuggest Edit
iBio is a biotechnology company and biologics contract development and manufacturing organization (CDMO). It develops products to treat fibrotic diseases, cancers, and infectious diseases. iBio's platforms and programs include CDMO services using its FastPharming technologies and glycaneering services; the development of therapeutics and vaccines, for which iBio conducts preclinical and clinical trials, and the production of proteins for research and further manufacturing use in 3D-bioprinting and other applications.
| Type | Public | |
| Founded | 2008 | |
| HQ | Bryan, TX, US | Map |
| Website | ibioinc.com | |
| Employee Ratings |
Recent NewsAll News
- iBio to Participate in the H.C. Wainwright Global Investment Conference
- iBio to Report Fiscal 2022 Third Quarter Financial Results and Provide Corporate Update on Thursday, May 12, 2022
- iBio Announces Presentation Highlighting Superior Glycosylation for Antibodies Produced in Plants
- iBio to Participate in the Oppenheimer 32nd Annual Healthcare Conference
Key People/Management at iBio
Thomas F. Isett
Chief Executive Officer & Chairman of the Board
Martin B. Brenner
Chief Scientific Officer
Randy J. Maddux
Chief Operating Officer
Lisa Middlebrook
Chief Human Resources Officer
Gary Sender
Director
Jack Owens
Director of Quality Assurance
iBio Financials and Metrics
iBio Revenue
iBio's revenue was reported to be $2.37 m in FY, 2021
| USD | |
|---|---|
Revenue (Q3, 2022) | 1.9m |
Gross profit (Q3, 2022) | 1.9m |
Net income (Q3, 2022) | (12.4m) |
EBIT (Q3, 2022) | (12.2m) |
Market capitalization (26-Jul-2022) | 51.3m |
Closing stock price (26-Jul-2022) | 0.2 |
Cash (31-Mar-2022) | 33.8m |
iBio's current market capitalization is $51.3 m.
Annual
Quarterly
| USD | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 | Q2, 2022 | Q3, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 45.0k | 651.0k | 527.0k | 108.0k | 314.0k | 96.0k | 410.0k | 705.0k | 765.0k | 211.0k | 168.0k | 1.9m |
Cost of goods sold | 493.0k | 40.0k | 113.0k | 48.0k | ||||||||
Gross profit | 272.0k | 171.0k | 55.0k | 1.9m | ||||||||
General and administrative expense | 2.9m | 3.4m | 2.8m | 3.0m | 2.6m | 3.2m | 5.6m | 5.8m | 5.3m | 6.6m | 8.4m | 8.5m |
Annual
Quarterly
| USD | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 | Q2, 2022 | Q3, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 16.0m | 13.4m | 9.0m | 2.1m | 3.6m | 10.0m | 77.5m | 91.3m | 84.6m | 62.8m | 39.2m | 33.8m |
Accounts Receivable | 119.0k | 155.0k | 117.0k | 75.0k | 224.0k | 75.0k | 300.0k | 180.0k | 387.0k | 207.0k | 111.0k | 1.0m |
Prepaid Expenses | 206.0k | 396.0k | 432.0k | 183.0k | 146.0k | 189.0k | 263.0k | 1.9m | 2.5m | 1.7m | 2.9m | 2.3m |
Inventories | 843.0k | 1.1m | 587.0k | 2.0m | 3.3m |
Annual
Quarterly
| USD | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 | Q2, 2022 | Q3, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (4.4m) | (8.9m) | (13.1m) | (4.5m) | (8.2m) | (12.9m) | (7.5m) | (15.7m) | (23.3m) | (8.9m) | (20.9m) | (33.2m) |
Depreciation and Amortization | 443.0k | 875.0k | 1.3m | 558.0k | 1.1m | 1.7m | 584.0k | 1.2m | 548.0k | 394.0k | 1.0m | 1.9m |
Inventories | (45.0k) | (273.0k) | ||||||||||
Accounts Payable | (16.0k) | (40.0k) | (29.0k) | (403.0k) | (549.0k) | (440.0k) | (12.0k) | 491.0k | (303.0k) | 79.0k | 872.0k | 1.6m |
| USD | FY, 2018 |
|---|---|
Revenue/Employee | 10.3k |
Debt/Equity | 1.6 x |
Debt/Assets | 0.6 x |
Financial Leverage | 2.7 x |
iBio Operating Metrics
| FY, 2016 | |
|---|---|
Patents Issued | 67 |
Patents Pending | 19 |
iBio Revenue Breakdown
iBio revenue breakdown by business segment: 94.4% from iBio, Inc. and 5.6% from iBio CDMO
iBio Cybersecurity Score
iBio Environment, Social & Governance (ESG) Ratings
iBio Online and Social Media Presence
0 Twitter followers
iBio has 0 Twitter Followers. The number of followers has decreased 100% quarter over quarter
iBio's Trends
iBio News and Updates
May 18, 2022
iBio to Participate in the H.C. Wainwright Global Investment Conference
BRYAN, Texas, May 18, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming® Manufacturing System, today announced that it will participate virtually in the H.C. Wainwri…
May 05, 2022
iBio to Report Fiscal 2022 Third Quarter Financial Results and Provide Corporate Update on Thursday, May 12, 2022
BRYAN, Texas, May 05, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, announced today that it will report its fiscal 2022 third quarter fina…
May 02, 2022
iBio Announces Presentation Highlighting Superior Glycosylation for Antibodies Produced in Plants
Data Showing Greater Glycosylation Homogeneity with the FastPharming® System Compared to Traditional Methods to be Presented at PEGS Conference & Expo
March 11, 2022
iBio to Participate in the Oppenheimer 32nd Annual Healthcare Conference
BRYAN, Texas, March 11, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, today announced that its Chairman & CEO, Tom Isett, will present…
February 14, 2022
iBio Reports Fiscal Second Quarter 2022 Financial Results and Provides Corporate Update
BRYAN, Texas, Feb. 14, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System®, today announces its financial results for the fiscal quarter ended December 31, 20…
February 07, 2022
iBio to Report Fiscal 2022 Second Quarter Financial Results and Provide Corporate Update on Monday, February 14, 2022
BRYAN, Texas, Feb. 07, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, announced today that it will report its fiscal 2022 second quarter fi…
iBio Blogs
June 21, 2022
Using the Power of Plants to Develop Novel Biopharmaceuticals
Biologics manufacturing company iBio is using plants as bioreactors to develop and manufacture therapeutics and vaccines with the goal of eliminating the significant cost and time associated with selecting, developing, and banking mammalian cell lines.
The post Using the Power of Plants to Develop N…
May 09, 2022
iBio Demonstrates Efficacy of an IL-2 Sparing Anti-CD25 Antibody Produced Using its FastPharming System for Treg Depletion in Cancer
Preclinical Data Presented at Frontiers in Cancer Immunotherapy 2022 Shows Potent Antibody-Dependent Cellular Cytotoxicity with Afucosylated Plant-Made Molecule NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceutic…
May 02, 2022
Changing the Paradigm of Cancer Drug Discovery and Development with Plants
In this article, iBio’s Chief Scientific Officer, Martin Brenner, DVM, Ph.D.; Chief Operating Officer, Randy Maddux; and oncology pipeline advisor, Steven King, explore how the iBio Drug Discovery Center is using the FastPharming System® to support faster and more efficient development of powerful n…
February 17, 2022
Plant-Based Biologics With iBio’s Randy Maddux
iBio COO Randy Maddux walks us through the Bryan, Texas-based biopharma’s attempt to turn the CHO cell biologic development paradigm on its ear with hydroponically-grown N. benthamiana. His company’s FastPharming approach to protein production, he says, could be modularized to speed cycle times and …
January 31, 2022
Vaccine Manufacturing: Chasing COVID’s Long Tail
By Mid-December 2021, the RAPS (Regulatory Affairs Professionals Society) COVID-19 Vaccine Tracker listed 91 active COVID-19 candidates in development around the globe. That’s in addition to the 25 vaccine products already approved by various international regulatory authorities. Just months ago, on…
July 08, 2021
iBio Establishes Oncology Drug Discovery Pipeline with Three New Antibody Programs
BRYAN, Texas, July 08, 2021 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, has taken another major step towards leveraging the speed and throughput of its proprietary, plant-based FastPharming Protein Expre…
iBio Frequently Asked Questions
When was iBio founded?
iBio was founded in 2008.
Who are iBio key executives?
iBio's key executives are Thomas F. Isett, Martin B. Brenner and Randy J. Maddux.
How many employees does iBio have?
iBio has 51 employees.
What is iBio revenue?
Latest iBio annual revenue is $2.4 m.
What is iBio revenue per employee?
Latest iBio revenue per employee is $46.5 k.
Who are iBio competitors?
Competitors of iBio include Alvotech, Tedor Pharma and KBI Biopharma.
Where is iBio headquarters?
iBio headquarters is located at 8800 HSC Pkwy, Bryan.
Where are iBio offices?
iBio has an office in Bryan.
How many offices does iBio have?
iBio has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies